Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination w… Read more
Market Cap & Net Worth: Hua Medicine (Shanghai) Ltd (HUMDF)
Hua Medicine (Shanghai) Ltd (PINK:HUMDF) has a market capitalization of $148.05 Million ($148.05 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #18891 globally and #6997 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hua Medicine (Shanghai) Ltd's stock price $0.15 by its total outstanding shares 986989557 (986.99 Million).
Hua Medicine (Shanghai) Ltd Market Cap History: 2021 to 2025
Hua Medicine (Shanghai) Ltd's market capitalization history from 2021 to 2025. Data shows change from $690.89 Million to $148.05 Million (-25.68% CAGR).
Hua Medicine (Shanghai) Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hua Medicine (Shanghai) Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.58x
Hua Medicine (Shanghai) Ltd's market cap is 0.58 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $444.15 Million | $17.60 Million | -$203.77 Million | 25.24x | N/A |
| 2023 | $200.16 Million | $76.61 Million | -$211.23 Million | 2.61x | N/A |
| 2024 | $148.05 Million | $255.89 Million | -$250.14 Million | 0.58x | N/A |
Competitor Companies of HUMDF by Market Capitalization
Companies near Hua Medicine (Shanghai) Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Hua Medicine (Shanghai) Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hua Medicine (Shanghai) Ltd Historical Marketcap From 2021 to 2025
Between 2021 and today, Hua Medicine (Shanghai) Ltd's market cap moved from $690.89 Million to $ 148.05 Million, with a yearly change of -25.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $148.05 Million | 0.00% |
| 2024 | $148.05 Million | -26.04% |
| 2023 | $200.16 Million | -54.93% |
| 2022 | $444.15 Million | -35.71% |
| 2021 | $690.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hua Medicine (Shanghai) Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $148.05 Million USD |
| MoneyControl | $148.05 Million USD |
| MarketWatch | $148.05 Million USD |
| marketcap.company | $148.05 Million USD |
| Reuters | $148.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.